Financials data is unavailable for this security.
View more
Year on year Lineage Cell Therapeutics Inc had revenues fall -39.16% from 14.70m to 8.95m, though the company grew net income from a loss of 26.27m to a smaller loss of 21.49m.
| Gross margin | 95.00% |
|---|---|
| Net profit margin | -229.91% |
| Operating margin | -260.70% |
| Return on assets | -19.77% |
|---|---|
| Return on equity | -29.95% |
| Return on investment | -22.80% |
More ▼
Cash flow in USDView more
In 2023, Lineage Cell Therapeutics Inc increased its cash reserves by 201.54%, or 24.06m. Cash Flow from Investing totalled 46.45m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 28.57m for operations while cash generated from financing totalled 6.42m.
| Cash flow per share | -0.1056 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.3505 |
|---|---|
| Tangible book value per share | 0.0475 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.48 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.002 |
|---|---|
| Total debt/total capital | 0.0021 |
More ▼
